VU0810464 (intraperitonealinjection; 30 mg/kg, 10 mg/kg; 30mg/kg; pre-treated 30 mins) produces a dose-dependent reduction of SIH response in Male C57BL/6J mice. To test if VU0810464 plays it role through Kir3 channel activation, VU0810464 (10 mg/kg) suppresses the SIH response in wild‐ type mice, but has no impact on Kcnj3/ mice[2].
VU0810464 (intraperitonealinjection; 30 mg/kg; 15, 30, 45, or 60 min post‐injection) displays a favourable distribution to the brain (Kp,uu = 0.83), has a improvement over ML297 (Kp,uu= 0.32). Clearance of VU0810464 is rapid,brain and plasma half-lives is 20 min in a PK study[2].
| Animal Model: | Male C57BL/6J mice, Kcnj3/ siblings female and male C57BL/6J mice |
| Dosage: | 10 mg/kg; 30mg/kg |
| Administration: | Intraperitonealinjection |
| Result: | Reduced stress‐induced hyperthermia (SIH), a physiological test of
anxiolytic efficacy in wild mice, but had no impact in and Kcnj3 (Girk1) / mice.
|
